Blue Owl Capital Holdings LP Acquires New Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Blue Owl Capital Holdings LP acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,046,025 shares of the company’s stock, valued at approximately $3,462,000. Pyxis Oncology makes up 1.0% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 23rd biggest position.

Other hedge funds also recently modified their holdings of the company. Vestal Point Capital LP acquired a new position in Pyxis Oncology during the 4th quarter worth about $792,000. Bank of New York Mellon Corp lifted its holdings in Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after buying an additional 149,522 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in Pyxis Oncology during the 1st quarter worth about $351,000. Cable Car Capital LLC acquired a new position in Pyxis Oncology during the 4th quarter worth about $111,000. Finally, SG Americas Securities LLC acquired a new position in Pyxis Oncology during the 1st quarter worth about $59,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Friday, August 16th. Finally, Stifel Nicolaus assumed coverage on Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $3.62 on Friday. Pyxis Oncology, Inc. has a one year low of $1.35 and a one year high of $6.85. The firm has a market capitalization of $213.17 million, a price-to-earnings ratio of -2.66 and a beta of 1.28. The business has a 50-day simple moving average of $3.61 and a 200 day simple moving average of $3.92.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. On average, sell-side analysts expect that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.